Suppr超能文献

钙增敏药物的作用机制。

Mechanisms of action of calcium-sensitizing drugs.

作者信息

Haikala H, Linden I B

机构信息

Orion-Farmos, Orion Research, Espoo, Finland.

出版信息

J Cardiovasc Pharmacol. 1995;26 Suppl 1:S10-9.

PMID:8907127
Abstract

This review compares the mechanisms of action of the calcium-sensitizing agents levosimendan, pimobendan, MCI-154, and EMD 53998. By using purified human recombinant troponin-C (cTnC), the role of cTnC as a target protein for these compounds was investigated. Accordingly, the calcium-dependent binding to cTnC in a cTnC-high-performance liquid affinity chromatography (HPLAC) column and the stabilizing effects of the compounds on the calcium-induced conformation of dansylated cTnC were studied. Only levosimendan showed calcium-dependent action on cTnC. Of the studied compounds, levosimendan was the most potent calcium sensitizer in skinned fiber experiments. Furthermore, EMD 53998 and MCI-154, but not levosimendan and pimobendan, increased myosin ATPase activity, indicating that they may enhance the cycling rate of myosin-actin crossbridges. By analyzing the velocity (dT/dt) of isometric tension development in paced papillary muscles, it was shown that levosimendan probably enhances the association rate but decreases the dissociation rate of myosin-actin crossbridges. These effects occurred before the peak twitch tension was achieved. Therefore, levosimendan does not seem to affect the actual relaxation phase. The other calcium sensitizers, however, appear to act mainly by decreasing the dissociation rate of crossbridges. The weak calcium-sensitizing effect of pimobendan may be based on indirectly mediated increase in affinity of cTnC for calcium. MCI-154 might act in a similar way but, like EMD 53998, MCI-154 also acts on myosin-actin crossbridges. We suggest that levosimendan binds in a calcium-dependent manner to the N-terminal domain of cTnC, which magnifies the extent of the contraction produced by cTnC when it is calcium-activated.

摘要

本综述比较了钙增敏剂左西孟旦、匹莫苯丹、MCI-154和EMD 53998的作用机制。通过使用纯化的人重组肌钙蛋白C(cTnC),研究了cTnC作为这些化合物靶蛋白的作用。因此,研究了在cTnC高效液相亲和色谱(HPLAC)柱中与cTnC的钙依赖性结合以及这些化合物对丹磺酰化cTnC钙诱导构象的稳定作用。只有左西孟旦对cTnC表现出钙依赖性作用。在所研究的化合物中,左西孟旦在皮肤纤维实验中是最有效的钙增敏剂。此外,EMD 53998和MCI-154,但不是左西孟旦和匹莫苯丹,增加了肌球蛋白ATP酶活性,表明它们可能提高肌球蛋白-肌动蛋白横桥的循环速率。通过分析起搏乳头肌等长张力发展的速度(dT/dt),表明左西孟旦可能提高肌球蛋白-肌动蛋白横桥的缔合速率,但降低其解离速率。这些作用发生在达到峰值抽搐张力之前。因此,左西孟旦似乎不影响实际的舒张期。然而,其他钙增敏剂似乎主要通过降低横桥的解离速率起作用。匹莫苯丹较弱的钙增敏作用可能基于间接介导的cTnC对钙亲和力的增加。MCI-154可能以类似的方式起作用,但与EMD 53998一样,MCI-154也作用于肌球蛋白-肌动蛋白横桥。我们认为左西孟旦以钙依赖性方式结合到cTnC的N末端结构域,这在cTnC被钙激活时放大了其产生的收缩程度。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验